Solventum Corporation Board of Directors
Science, Technology and Quality Committee Charter
Effective as of April 1, 2024

A. Purpose: The responsibility of the Science, Technology and Quality Committee (the "Committee") of the Board of Directors (the "Board") of Solventum Corporation (the "Company") is to oversee the significant scientific and technological aspects of the Company's research and development and business development activities.

B. Membership: The Committee's membership is determined by the Board upon recommendation of the Governance Committee and consists of at least three directors. The Board shall appoint one member of the Committee as Chair ("the Committee Chair"). The members of the Committee shall meet the independence requirements of the New York Stock Exchange.

C. Authority and Responsibilities: The Committee is responsible for providing general oversight of the significant scientific and technological aspects of the Company's research and development and business development activities. To fulfill its responsibilities, the Committee shall:

1. Monitor and review the overall strategy, direction and effectiveness of the Company's research and development and business development activities.

2. Review management's strategy and allocation of resources for research and development and business development activities, including product line extensions, new product platforms and licensing and distribution arrangements.

3. Oversee risk management in the area of product quality and safety, including:

    a. Review the adequacy and effectiveness of the Company's strategies and practices with respect to (i) compliance with laws and regulations administered by the U.S. Food and Drug Administration ("FDA") and similar state, local and foreign agencies, (ii) the safety and quality of the Company's products and (iii) other material aspects of its quality and compliance functions; and

    b. Periodic review of reports regarding significant compliance matters from the senior executives in charge of the Company's quality and compliance functions, including (i) the Company's efforts to comply with key FDA mandates, including any enforcement actions such as warning letters or consent decrees, or remediation programs directed to addressing persistent Form FDA 483 observations and (ii) the results of quality and quality system assessments.

4. Oversee the quality and regulatory aspects of the Company's research and development programs, including the review and approval process with FDA and

similar state, local and foreign agencies and any identified quality or regulatory issues related to the Company's research and development programs.

5. Oversee the Company's policies, programs and performance related to medical affairs, including identified and potential safety issues affecting the Company's products and services and compliance with applicable laws and regulations.

6. Review such other topics as are delegated to the Committee by the Board.

7. Meetings, Reports, Charter Review and Performance Evaluation.

   a. The Committee shall hold regular meetings of the Committee with such frequency and at such intervals as the Committee shall determine is necessary to carry out its duties and responsibilities, but in any case, not less than three times a year. A majority of the members shall constitute a quorum. A majority of the members present shall decide any matter brought before the Committee. The Committee Chair shall preside at each meeting. In the event the Committee Chair is not present at a meeting, the Committee members present at that meeting shall designate one of its members as the acting chair of such meeting.

   b. The Committee shall report significant matters arising from its meetings to the Board.

   c. The Committee shall review and reassess the adequacy of this Charter at least annually and submit any changes to the Board for approval.

   d. The Committee shall conduct an annual performance evaluation of the Committee.

D. Delegation of Authority: The Committee shall have the authority to delegate its authority to a subcommittee composed solely of one or more members of the Committee as the Committee may deem appropriate, to the extent permitted by applicable law, New York Stock Exchange rules, the Company's bylaws, and applicable resolutions of the Board.

E. Outside Advisors: The Committee shall have the authority and appropriate funds to retain such outside legal, accounting or other advisors, as the Committee may deem appropriate in its sole discretion. The Committee shall have sole authority to approve related fees and retention terms.